ML060670337
| ML060670337 | |
| Person / Time | |
|---|---|
| Site: | Monticello |
| Issue date: | 03/06/2006 |
| From: | Nuclear Management Co |
| To: | Office of Nuclear Reactor Regulation |
| beltz T, NRR/DORL/LPL3-1, 301-415-3049 | |
| Shared Package | |
| ML060670035 | List: |
| References | |
| Download: ML060670337 (18) | |
Text
NMC Committed to Nuclear Excellence
§~rtW Y f.Full W-..'.-t-N are]in source Term am L Scope lh 6, 20036 7 ;S *:: Committed to Nuclear Excellence I/ ..~., I 1 I SC w .wSupportR.O.in
~.Montcell AST',,.urpose view larch 2007 in January 2007 background related to i t :1, , -J..N Committed to Nuclear Excellence 2
p Project Team..Manager of Proj ects: Nclear Licensing M Poject Engineer: Nuclear Licensing Ei Pat Burke[anager: Gabor Salamon Melissa Limbeck rgineer: Rick Loeffler Kathryn Shriver gineering Support: e .i, W 4 .W-':.. :-:.-Ff'.:',:>,,.,. ,;,,, F"':;,. f-:L. .0 ..X." e;*" \;NMC Committed to Nuclear Excellene:%3 s2: -22r to < Fi i g Ff' i .6-.^ ',: 'W§:-".'*, ,<: -., '.;t<;C!ffit'3*
.'t' : .. ' ' .. '- ..' < "', .sp W. ,, P.,- f\e, r kiP.' ,,i i S. % es C.' f 'W.'S,.'
- 5L.;t )..b.;
- , ,, .,.: r."',ei, ,'. .' ..'[Er'.H,-'f.".
,;: -, _ n----u -rcope r .v .... ;.... ..L .-X...e ... (. ...r> 8; C t 1R*
- ffi-;
- t;.,. .X.. .e: ?.Wi .s<,-Technlcal k-':.- -.t..-.:... i l f.; r .. L ..L ':-.S. ;......S.<d ...;,; .n r;: ._, X, .v v- *_r ^ a i__ h l,"i' ';;.__. ... _Agenda AST Accident Analysis lom Configuration Specification Changes...I..0I ,4 .II I I"I, Ni pi Committed to Nuclear Excellence p I 4
-sg e -+Syss-r.; rlr. < .e, .,;' f;> ft4,- C t_.t_ :. o { { _ti4z
- .*£9.S .,'t.".',;.,-= ..,.-, ..- .g .. ;. -i .f., ->, j, t f ; ..
- D@'"'S' :. 9 9 A A A n acclctent Analysls wource Term L.ei i ' i t : ..: rN'X^;'
M. *: :.; -?.:: .- -* Consistent with RG 1. 1 83-Compliance Matrix included in license.amentlmpnt rpniiPt-4W -J A.JJIL. J L. J. 1.. _ _ ,-'Core inventory* Full scope core k .- '* .:.-.: .calculation revision inventory using ORIGEN e ss_I I.NM Committed to Nuclear Excellence
.4-,I 5
.ident Anaysis Dispersion Factors F tfF eCalculation previously submitted with AST KAddiin A lsdispersion factors for new receptor[>loation identified during GL 2003-01 test[BERM.i Changes to meteorological data and release height identified in AST-FHA Assumptions Results:j ,Committed to NucleaN... ..'sr E e--r Excellence
- .
'A'..kccident AAssumptions Results AAnalysis
-LOCA' ....e s 't ~ ". .. .. ..W* Standby Liquid Control (SBLC) model*Ste'am line deposition model design considerations, schedule"I .-A I.Committed to Nuclear Excellence.f 7 j\.i*.
I;Acid ent.*MSIV Leakag(V .Exemption Add separate Pathway (incl Exemption to requirements:
"'2 '.2 ,:.Analysis -LOCA e / 1OCFR50 Appendix J TS requirements for Main Steam uding MSIVs) leakage Appendix J, Option B I3/4for Main Steam Pathway leakage..c , Committed toNuclear Excellence
_ '8 s. ,t r_ w .-:-r -.,,, _ w .,, s :_@ :Rl-.,::a,, ' '. ' -rR -< -X, ._..s'.'s.' Sni. .',5e Hq 4,:,,>:, ..,, ,;..E, k ..ffi ...,,. ;-w. .:-. .r ,-:= a N.,'.\>:. .; '.- !s-. .Vt:AccidexIt
?.2.,. .., ... , K ..W.. --r..; .0 Assumptions
.: ...............
..... ..:tonservatively
.. ,.i.,>-=<.,;
.X TO .................
tO Cs a--0-19 V 91 1 91WCthk....... ..... z A , ..: ,.-S .+. .: -..-......, .,. .,... ._o,^ Kesu ts........ ,.X ........ , ; .-nfz ->:: :.,.., .. :.-: -.W, .. ..> > / : i'.: :.-. ., -.: (,, .,.. ..t t ;. ;; :., 4, ....w t- f --or= S ;, E .,! _,,, -.M .._.
."t; Z ' _: _, ;. ....-'.'_ ', .,. .:*i+s- -t 1 '-, 'i i.; 'i.': 1,. .i .W.'.-..: -":; S r Z o * >
- 0: D o-t ,. .' e J : '.,- -S t q .wn ._;s * ; f Knalysis -MSLBA modeled as 2 hour2.314815e-5 days <br />5.555556e-4 hours <br />3.306878e-6 weeks <br />7.61e-7 months <br /> ground! -.I w...I I I I t"..' r II II I 1.I II Committed to Nuclear Excellen c -I8.9 Accdent Analysis C .* Assumptions J operating case assumes ogas S. a ' ' a ' '. .' a a :L ' --ai tre:atmen sysna Analpi~ss gCRDiuAg)i Dir bypassed*Isolated condenser case (includes provision fo: ;-r MVP trip)'Results Committed to Nuclear ExcellM 1 0.F C: en Accident AnlyisFl mtions* hanges from previously submitted o~reviseu source term andci ispersion* .-Will supersede previously submitte(whn approved-No impact on FHA currently under re's.,,.Results
-V -HiA FHA tactor)I FHA'S ,iew view.Commiffed to Nuclear Excellence
,/ ..li .I1 I'*.4,
- r. " ._. ' o:;_-0Control Roomi onfilguration
- H .t' .: .- '! " '.,,.t .', :"o-., X -' .' _[' ,iK
- fl , 4:Relationship to AST analysis assumptions
-o to 7 :s.. 4 ' .: .¢,a*, Si,, {, , $ ..:.,'7'iis^;-..,!,;i..
S .aif K .\ i .- -., ' _ _ _Analysis assumptions testing in June 2003 confirmed by tracer-gas
'..12 Techlical Specification Changes* f :Control-Room Habitability instrumentation
- MVP isolation instrumentation SnB LC requirements
- - Reactor coolant chemistry (iodine)
- Control Room Habitability requirqients-
- Primary Containment Isolation Valves* ITS pages submitted as supplement
- t. ttdt Committed to Nuclear Excellenc
-13 Thank You ,~ IV Ce;Commited to Nuclear Excellence N.,
Accident Dose Summary Table 2.2-4 LOCA CR Operator Dose Regulatory Source TEDE Limit*(TEDE)Internal (Inhalation)
Dose 2.74 rem External (Shine) Dose 0.66 rem Total Dose: 3.40 rem 5 rem*Per RG 1.183 and 10 CFR 50.67 Table. 2.2-5 LOCA Doses at EAB and LPZ Locations Regulatory Location TEDE Limit**(TEDE)EAB Dose* 1.31 rem 25 rem LPZ Dose 1 .72 rem 25 rem* The EAB dose represents the maximum 2-hour TEDE over the accident period**Per RG 1.183 and 10 CFR 50.67 Table 2.3-2 MSLBA CR Operator Doses Regulatory Source Term Case TEDE Limit*(TEDE)Dose with maximum equilibrium 0.33 rem 5 rem radioiodine
.03re 5rm Dose with pre-accident radioiodine I3.25 rem 5 rem spiking 3.25 rem _5_rem* Per RG 1.183 and 10 CFR 50.67 Table 2.3-3 MSLBA Doses at EAB and LPZ Locations (Doses with maximum equilibrium radioiodine)
Regulatory Location TEDE Limit*(TEDE)EAB Dose 0.11 rem 2.5 rem LPZ Dose 0.02 rem 2.5 rem*Per RG 1.183 Table 2.3-4 MSLBA Doses at EAB and LPZ Locations (Doses with pre-accident radio~iodine sp ing)Regulatory Location TEDE Limit*(TEDE)EAB Dose 1.05 rem 25 rem LPZ Dose 0.20 rem 25 rem*Per RGI.183 and 10 CFR 50.67 Table 2.4-3 CRDA CR Onerator Dose Regulatory Location TEDE Limit*(TEDE)CR Operator Dose (SJAE 1.70 rem 5 rem Operation)
CR Operator Dose (MVP Isolation) 0.56 rem 5 rem*Per RG 1.183 and 10 CFR 50.67 Table 2.4-4 CRDA Doses at EAB and LPZ Locations Regulatory Location TEDE Limit*(TEDE)EAB Dose (SJAE Operation) 1.73 rem 6.3 rem EAB Dose (MVP Isolation)
.0.18 rem 6.3 rem.LPZ Dose (SJAE Operation) 0.79 rem 6.3 rem LPZ Dose (MVP Isolation 0.08 rem 6.3 rem*PerRG 1.183 Table 2.5-3 FHA CR Operator Dose Regulatory Location TEDE Limit*_ _ (TEDE)CR Operator Dose 4.29 rem 5 rem* Per RG 1.183 and 10 CFR 50.67 Table 2.5-4 FHA Offsite Dose Regulatory Location TEDE Limit*._ __ (TEDE)EAB Dose 1.61 rem 6.3 rem LPZ Dose 0.31 rem 6.3 rem* Per RG 1.183